Key Priorities For Immunohistochemical Testing In Predicting Cervical Cancer Recurrence
Annotatsiya
Cervical cancer is an urgent problem due to its high morbidity, its growth tendency in women of reproductive age, and late presentation. As a result of insufficiently effective surgical and/or radiation treatment of the primary tumor, local recurrences occur in 10-40% of treated patients, and distant metastases in 35% of patients [10]. The first place according to the frequency of distant metastasis in RCC patients is occupied by para-aortic lymph nodes (31.2%), the second - lungs (16.1%), the third - bones (12.9%) [9]. Treatment of recurrent and generalized cervical cancer is a complex and unresolved problem of modern oncology due to the extremely limited range of possible therapeutic measures. The leading role in conservative therapy of cervical cancer relapses and metastases is played by highly toxic, but not specific cytostatics, which aggravates the condition of patients and the immunological failure of the organism [11].